Cellectis S.A. (EPA:ALCLS)
France
· Delayed Price · Currency is EUR 2.450
+0.040 (1.66%)
Jun 26, 2026, 5:35 PM CET
Cellectis Employees
As of December 31, 2025, Cellectis had 229 total employees, including 224 full-time and 5 part-time employees. The number of employees increased by 7 or 3.15% compared to the previous year.
Employees
229
Change (1Y)
7
Growth (1Y)
3.15%
Revenue / Employee
€286,981
Profits / Employee
€256,866
Market Cap
177.87M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Transgene | 145 |
| Innate Pharma | 164 |
| Sensorion | 63 |
| Valerio Therapeutics Société anonyme | 25 |
| Adocia | 73 |
| Valneva SE | 674 |
| OSE Immunotherapeutics | 64 |
| ABIONYX Pharma | 49 |
Cellectis News
- 2 days ago - Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026 - GlobeNewsWire
- 17 days ago - Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress - GlobeNewsWire
- 17 days ago - Cellectis Slides: FY 2026 - Filings
- 18 days ago - Cellectis (CLLS) Receives FDA RMAT Designation for CAR-T Therapy, Shares Rise - GuruFocus
- 18 days ago - Cellectis (CLLS) Achieves RMAT Designation for CAR-T Therapy - GuruFocus
- 18 days ago - Cellectis granted RMAT designation for lasmecabtagene timgedleucel from FDA - TheFly
- 18 days ago - Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL - GlobeNewsWire
- 24 days ago - Monthly information on share capital and company voting rights - GlobeNewsWire